Permethrin

As a classic antiparasitic drug widely used worldwide, permethrin belongs to the synthetic pyrethroid class of anthelmintics. It can interfere with the sodium channels on the nerve cell membranes of parasites, block the conduction of nerve signals, and cause paralysis and death of the parasites. It has both contact toxicity and stomach toxicity, and has extremely low toxicity to warm-blooded animals. It has a wide range of clinical indications: it can be used externally to treat head lice, pubic lice infections and scabies, and can also be used to prevent and control crop pests and household sanitary pests. It also has important application value in the malaria vector control scenario in the field of public health, covering people of all age groups (the use concentration for children needs to be adjusted under medical advice).

The global permethrin market size was approximately USD 320 million in 2023, and the compound annual growth rate from 2024 to 2030 is expected to remain at around 4.7%. The growth drivers mainly come from the demand for parasite prevention and control in tropical regions, the expansion of deworming scenarios in animal husbandry, and the popularization of household hygiene disinfection products. The current competitive landscape is characterized by the dominance of generic products. After the patent of the original research product expired, enterprises in China and India, with their cost advantages, occupy more than 70% of the global API supply share. In the procurement of domestic public medical institutions, the winning bid price of external preparations has dropped by more than 60% compared with the initial stage of the original research product's launch, and the accessibility has been greatly improved.

The original research enterprise of permethrin is GlaxoSmithKline, with the original trade name Nix. The core compound patent expired globally in 1999. At present, the mainstream marketed dosage forms include 1% lotion and 5% cream, with conventional specifications of 30g per tube and 60ml per bottle. The original research product has been included in the FDA Reference Listed Drug Catalog. Up to now, there is no approved A-status registration number for permethrin on the API registration platform of the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China. The domestically approved marketed preparations are mainly generic external lotions and creams, and there is no import declaration record of the original research product. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of permethrin impurity reference standards, which can meet the full-process testing needs from R&D and declaration to mass production quality control. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. All reference standards meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can provide reliable reference substance support for the R&D and quality research of APIs and preparations of relevant enterprises.